Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus
Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalen...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2015-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=19;spage=2625;epage=2631;aulast=Wang |
id |
doaj-7c4f82888a5540768360bf1ce0ba1a9f |
---|---|
record_format |
Article |
spelling |
doaj-7c4f82888a5540768360bf1ce0ba1a9f2020-11-25T01:03:00ZengWolters KluwerChinese Medical Journal0366-69992015-01-01128192625263110.4103/0366-6999.166038Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C VirusYe WangHui-Ying RaoXing-Wang XieLai WeiBackground: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naÏve GT1b CHC patients. Methods: Direct sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naÏve patients infected with genotype 1b hepatitis C virus (HCVs). Results: One hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing. Conclusions: The majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work.http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=19;spage=2625;epage=2631;aulast=WangAntiviral Resistance; Direct Antiviral Agents; Hepatitis C Virus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ye Wang Hui-Ying Rao Xing-Wang Xie Lai Wei |
spellingShingle |
Ye Wang Hui-Ying Rao Xing-Wang Xie Lai Wei Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus Chinese Medical Journal Antiviral Resistance; Direct Antiviral Agents; Hepatitis C Virus |
author_facet |
Ye Wang Hui-Ying Rao Xing-Wang Xie Lai Wei |
author_sort |
Ye Wang |
title |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus |
title_short |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus |
title_full |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus |
title_fullStr |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus |
title_full_unstemmed |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naÏve Patients Infected with Genotype 1b Hepatitis C Virus |
title_sort |
direct-acting antiviral agents resistance-associated polymorphisms in chinese treatment-naïve patients infected with genotype 1b hepatitis c virus |
publisher |
Wolters Kluwer |
series |
Chinese Medical Journal |
issn |
0366-6999 |
publishDate |
2015-01-01 |
description |
Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naÏve GT1b CHC patients.
Methods: Direct sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naÏve patients infected with genotype 1b hepatitis C virus (HCVs).
Results: One hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing.
Conclusions: The majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work. |
topic |
Antiviral Resistance; Direct Antiviral Agents; Hepatitis C Virus |
url |
http://www.cmj.org/article.asp?issn=0366-6999;year=2015;volume=128;issue=19;spage=2625;epage=2631;aulast=Wang |
work_keys_str_mv |
AT yewang directactingantiviralagentsresistanceassociatedpolymorphismsinchinesetreatmentnaivepatientsinfectedwithgenotype1bhepatitiscvirus AT huiyingrao directactingantiviralagentsresistanceassociatedpolymorphismsinchinesetreatmentnaivepatientsinfectedwithgenotype1bhepatitiscvirus AT xingwangxie directactingantiviralagentsresistanceassociatedpolymorphismsinchinesetreatmentnaivepatientsinfectedwithgenotype1bhepatitiscvirus AT laiwei directactingantiviralagentsresistanceassociatedpolymorphismsinchinesetreatmentnaivepatientsinfectedwithgenotype1bhepatitiscvirus |
_version_ |
1725202738733645824 |